AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
MWN-AI** Summary
AIM ImmunoTech Inc. is demonstrating significant momentum in its clinical development efforts, particularly focusing on its lead investigational drug, Ampligen® (rintatolimod), for the treatment of pancreatic cancer. Recently, the company shared encouraging mid-year results from its Phase 2 clinical study, which is assessing Ampligen in combination with AstraZeneca’s immune checkpoint inhibitor, Imfinzi® (durvalumab). The study reports indicate positive outcomes with no significant toxicity and improvements in progression-free survival (PFS) and overall survival (OS) for patients with metastatic pancreatic cancer who have stable disease post-FOLFIRINOX treatment.
CEO Thomas K. Equels expressed optimism about the company’s resilience amidst challenging market conditions. The recent resumption of trading on the NYSE American, alongside the successful closure of an $8 million public equity offering, has bolstered AIM’s financial position, providing a funding runway of approximately 12 months. This new capital will support the advancement of their clinical trials and regulatory initiatives aimed at securing drug approval.
AIM’s commitment to pancreatic cancer is further evidenced by the receipt of U.S. and EU Orphan Drug designations and the granting of patents related to the manufacturing methods of therapeutic dsRNA and the combination of Ampligen with PD-L1 drugs. These regulatory designations and intellectual property achievements are pivotal as AIM seeks to establish a clear path toward registration for Ampligen.
As AIM ImmunoTech continues to present its oncology data in various scientific forums, the company reinforces its dedication to unlocking Ampligen’s potential and maximizing value for its stakeholders. However, it cautions investors about the uncertainties inherent in clinical development and regulatory processes.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) is positioning itself favorably in the biotechnology sector, focusing heavily on the clinical development of its lead product, Ampligen® (rintatolimod), particularly in the realm of pancreatic cancer. Recent updates indicate a robust trajectory, especially following a mid-year report highlighting positive outcomes from its Phase 2 clinical study examining Ampligen® in conjunction with AstraZeneca’s Imfinzi® (durvalumab). These results suggest both favorable progression-free survival (PFS) and overall survival (OS) rates, alongside low toxicity levels, which are critical benchmarks for oncological drug approval.
The company's successful completion of an $8 million public equity offering has strengthened its cash position, providing operational funding for approximately 12 months. This financial cushion, coupled with the resumption of trading on the NYSE American, signals a renewed confidence among investors and stakeholders. AIM’s CEO, Thomas K. Equels, emphasized a clear focus on registration paths and regulatory initiatives, suggesting that AIM is strategically aligning its resources to maximize shareholder value.
Moreover, the grant of U.S. and EU orphan drug designations for pancreatic cancer enhances the outlook for Ampligen®, potentially facilitating expedited development timelines and market exclusivity. With pivotal data already garnering attention at major scientific congresses, AIM ImmunoTech is enhancing its visibility in a competitive marketplace.
Investors should monitor AIM closely, as any further positive clinical results or regulatory approvals could catalyze substantial stock appreciation. However, it's vital for potential investors to remain aware of inherent risks associated with biotech investments, including the uncertain timeline for drug approvals and market acceptance. Balancing these risks with AIM's current positive trajectory could foster strategic investment decisions in the near term.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Primary focus on pancreatic cancer
Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS
Bolstered cash position provides runway to fund operations for approximately 12 months
OCALA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent key financial milestones and firmly stated its focus on advancing clinical trials of Ampligen® for the treatment of pancreatic cancer, with the ultimate goal of achieving drug approval.
AIM ImmunoTech CEO Thomas K. Equels stated, “We have emerged strong despite significant macro, sector and market-related headwinds. Our perseverance, dedication to patients, belief in the potential of Ampligen and commitment to all stakeholders have enabled us to successfully navigate through an extremely challenging period. With our regained listing status, the closing of a significant equity financing and the continued advancement of our pipeline and strengthened patent estate, we are well poised to build momentum and drive value for all stakeholders.
“Our growing body of positive data with Ampligen has provided the opportunity to focus our resources and priorities to our lead indication in pancreatic cancer. We believe establishing a clear path to registration and the execution of our clinical and regulatory initiatives will unlock the full potential of this important asset and shareholder value,” added Equels.
Significant Achievements
- Resumed trading on the NYSE American;
- Closed public equity offering, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months;
- Reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (the “DURIPANC” study) (See: NCT05927142 );
- Granted U.S. patent covering methods of manufacturing therapeutic dsRNA, including Ampligen;
- Granted U.S. patent for Ampligen in combination with PD-L1 drugs for the treatment of cancer;
- Granted U.S. and EU Orphan Drug designations for pancreatic cancer;
- Ampligen oncology data presented at scientific congresses including the Annual Meeting of the American Association of Immunologists and U.S.-Poland Science and Technology Symposium 2025;
For more information, please visit the Company’s website at aimimmuno.com .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
How does AIM ImmunoTech Inc. AIM plan to leverage the positive data from the Phase 2 clinical study of Ampligen® in combination with Imfinzi® to expedite regulatory approval for pancreatic cancer treatments?
Given the bolstered cash position from the recent equity offering, how will AIM ImmunoTech Inc. AIM allocate funds specifically towards the DURIPANC study and other pivotal trials for Ampligen®?
What strategies does AIM ImmunoTech Inc. AIM have in place to address the risks and uncertainties mentioned in the mid-year report, particularly concerning the approval of Ampligen® for pancreatic cancer?
Can AIM ImmunoTech Inc. AIM provide insights on the potential market impact and competitive landscape for Ampligen® if it achieves market approval for use in pancreatic cancer therapies?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
